ArticleNature communications2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Oncolytic virus therapy for hepatocellular carcinoma: A bibliometric analysis of research landscapes, hotspots, and clinical transformation trends from 2000 to mid-2025.Human vaccines & immunotherapeutics · 2026Review
- CSDE1 in tumour immunology: spatiotemporal translational reprogramming and immune microenvironment remodeling.Journal of translational medicine · 2026Review
- CSDE1 promotes viral immune evasion through RNA-dependent and phosphorylation-modulated liquid-liquid phase separation.Nature communications · 2026Article
- CSDE1 Drives Glycolysis and the Progression of Prostate Cancer Through RAC1-Dependent RAS/MAPK Activation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Review
- Reprogramming tumor immunity through APOBEC3s-mediated mutagenesis: from genome instability to immune checkpoint interactions.Frontiers in immunology · 2026Review
- CSDE1 depletion inhibits tumor progression through enhancing B-cell infiltration in NSCLC.Cell death & disease · 2025Article
- T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends.Current oncology (Toronto, Ont.) · 2025Review
- Structures of vesicular stomatitis virus glycoprotein G alone and bound to a neutralizing antibody.PLoS pathogens · 2025Article
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- Activation and Evasion of the FEAR Pathway by RNA Viruses.bioRxiv : the preprint server for biology · 2025Article
- The role of ADAR1 in human pathophysiology.Frontiers in cell and developmental biology · 2025Review
- Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations.Viruses · 2024Review
- APOBEC3B expression in 293T viral producer cells drives mutations in chimeric antigen receptors and reduces CAR T cell efficacy.Molecular therapy. Oncology · 2024Article
- Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.Nature communications · 2024Article
- CD8Journal of translational medicine · 2024Review
- Chimerization of the Anti-Viral CD8Research square · 2023Article
- Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.Molecular therapy oncolytics · 2023Article
- A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Timothy KottkeDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Jason TonneDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Laura EvginDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Christopher B DriscollDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8629-1798
Jacob van VlotenDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3752-9499
Victoria A JenningsChester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Amanda L HuffDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Brady ZellDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Jill M ThompsonDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Phonphimon WongthidaDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Jose PulidoDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
Matthew R SchuelkeDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8399-1537
Adel SamsonLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Peter SelbyLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Elizabeth IlettLeeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0000-0002-9875-0322
Mark McNivenDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Lewis R RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7885-8574
Mitesh J BoradDivision of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Hardev PandhaFaculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Kevin HarringtonChester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.ORCID 0000-0002-6014-348X
Alan MelcherChester Beatty Laboratories, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Richard G VileDepartment of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. vile.richard@mayo.edu.ORCID 0000-0003-2192-9372
Mayo Clinic in Arizona · USUniversity of Leeds · GBInstitute of Cancer Research · GBUniversity of Surrey · GB
Funding
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5MProject 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Zongming Eric Chen · 2018 to 2026
$20.5MPhD Training Program in Virology and Gene TherapyT32AI132165 · NIAID · MAYO CLINIC ROCHESTER · PI ROBERTO B. CATTANEO · 2018 to 2026
$1.3MCancer Research UK 21855Cancer Research UK 29039NCI NIH HHS P50 CA108961NCI NIH HHS P50 CA210964NIAID NIH HHS T32 AI132165
Abstract
In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors predictably express a point-mutated CSDE1
Indexed as
AnimalsCancer VaccinesCell Line, TumorDNA-Binding ProteinsFemaleHumansImmunotherapyInterferon-betaMiceMice, Inbred C57BLMutationOncolytic VirotherapyOncolytic VirusesRNA-Binding ProteinsT-LymphocytesVesicular stomatitis Indiana virusCancer VaccinesCSDE1 protein, humanDNA-Binding ProteinsInterferon-betaRNA-Binding Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.